Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 3/20 | 0.42 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.42 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | GRN | P28799 | 1/20 | 0.41 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.41 |
| ▸ | METAP2 | P50579 | 1/20 | 0.40 |
| ▸ | METAP1 | P53582 | 1/20 | 0.40 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2164841 | 1.00 | SLC1A3 (0.42) | SLC1A3SLC1A2SLC1A1LTA4HGRN | |
| SCHEMBL7229428 | 1.00 | SLC1A3 (0.42) | SLC1A3SLC1A2SLC1A1LTA4HGRN | |
| SCHEMBL5981288 | 1.00 | SLC1A3 (0.42) | SLC1A3SLC1A2SLC1A1LTA4HGRN | |
| SCHEMBL5980910 | 1.00 | SLC1A3 (0.42) | SLC1A3SLC1A2SLC1A1LTA4HGRN | |
| SCHEMBL1931750 | 0.98 | SLC1A3 (0.40) | SLC1A3SLC1A2SLC1A1LTA4HGRN | |
| SCHEMBL1931748 | 0.98 | SLC1A3 (0.40) | SLC1A3SLC1A2SLC1A1LTA4HGRN | |
| SCHEMBL3353915 | 0.98 | SLC1A3 (0.40) | SLC1A3SLC1A2SLC1A1LTA4HGRN | |
| SCHEMBL7495280 | 0.93 | SLC1A3 (0.40) | SLC1A3SLC1A2SLC1A1OR51E2 | |
| SCHEMBL3346213 | 0.93 | SLC1A3 (0.40) | SLC1A3SLC1A2SLC1A1OR51E2 | |
| SCHEMBL5981459 | 0.89 | ALDH1A1 (0.43) | LTA4HGRNSORT1METAP2METAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8530448-B2 | Compounds and methods for inhibiting selectin-mediated function | GLYCOMIMETICS, INC. (US) | 2013-09-10 | — | — | US | claimed |
| EP-1482790-B1 | PESTICIDAL COMPOSITION COMPRISING A LACTATE ESTER AS CRYSTAL GROWTH INHIBITOR | MAKHTESHIM CHEM WORKS LTD (IL) | 2008-08-06 | — | — | EP | claimed |
| EP-0979241-B1 | (3R)-3-AMINO-4-CARBOXYBUTYRALDEHYDE DERIVATIVES INHIBITING THE RELEASE OF INTERLEUKIN-1/BETA | IVAX DRUG RES INST LTD (HU) | 2006-03-01 | — | — | EP | claimed |
| US-6593300-B1 | Inhibitors of the interleukin-1 beta converting enzyme | GYOGYSZERKUTATO INTEZET KFT. (HU) | 2003-07-15 | — | — | US | claimed |
| EP-0979241-A1 | (3R)-3-AMINO-4-CARBOXYBUTYRALDEHYDE DERIVATIVES INHIBITING THE RELEASE OF INTERLEUKIN-1/BETA | GYOGYSZERKUTATO INTEZET KFT. (HU) | 2000-02-16 | — | — | EP | claimed |
| WO-1998049189-A1 | (3R)-3-AMINO-4-CARBOXYBUTYRALDEHYDE DERIVATIVES INHIBITING THE RELEASE OF INTERLEUKIN-1/BETA | Gyógyszerkutató Intézet Kft. (HU) | 1998-11-05 | — | — | WO | claimed |
| JP-9328692-A | — | — | None | — | — | JP | disclosed |
| US-12466805-B2 | Pharmaceutical compounds | ALMAC DISCOVERY LIMITED (GB) | 2025-11-11 | — | — | US | disclosed |
| CN-109790146-B | Pharmaceutical compounds | 阿尔麦克探索有限公司 | 2022-08-23 | — | — | CN | disclosed |
| EP-3490982-B1 | PHARMACEUTICAL COMPOUNDS | ALMAC DISCOVERY LTD (GB) | 2022-04-20 | — | — | EP | disclosed |
| US-20220002264-A1 | PHARMACEUTICAL COMPOUNDS | ALMAC DISCOVERY LIMITED (GB) | 2022-01-06 | — | — | US | disclosed |
| US-11174291-B2 | Silstatin compounds | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2021-11-16 | — | — | US | disclosed |
| US-11053213-B2 | Pharmaceutical compounds | ALMAC DISCOVERY LIMITED (GB) | 2021-07-06 | — | — | US | disclosed |
| EP-0836610-A1 | DIGLYCOSYLATED 1,2-DIOLS AS MIMETICS OF SIALYL-LEWIS X AND SIALYL-LEWIS A | Novartis AG (CH) | 1998-04-22 | — | — | EP | disclosed |
| JP-H09328692-A | COLORED FLAME-GENERATING LIQUID FUEL AND COLORED FLAME-GENERATING SOLID FUEL | OOZEKI FUMITERU | 1997-12-22 | — | — | JP | disclosed |
| EP-0629212-B1 | NEW ANTICOAGULANT PEPTIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS WELL AS A PROCESS FOR THE PREPARATION THEREOF | GYOGYSZERKUTATO INTEZET (HU) | 1997-10-08 | — | — | EP | disclosed |
| WO-1997017363-A1 | THROMBIN INHIBITORS | AKZO NOBEL N.V. (NL) | 1997-05-15 | — | — | WO | disclosed |
| WO-1997001569-A1 | DIGLYCOSYLATED 1,2-DIOLS AS MIMETICS OF SIALYL-LEWIS X AND SIALYL-LEWIS A | NOVARTIS AG (CH) | 1997-01-16 | — | — | WO | disclosed |
| EP-0629212-A1 | NEW ANTICOAGULANT PEPTIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS WELL AS A PROCESS FOR THE PREPARATION THEREOF. | GYOGYSZERKUTATO INTEZET (HU) | 1994-12-21 | — | — | EP | disclosed |
| WO-1993018060-A1 | NEW ANTICOAGULANT PEPTIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS WELL AS A PROCESS FOR THE PREPARATION THEREOF | Gyógyszerkutató Intézet Kft. (HU) | 1993-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12466805-B2 | Pharmaceutical compounds | USP19, USP18, UBE2I | SLC1A3 4309/4885SLC1A2 4518/4885SLC1A1 4147/4885 |
| US-20220002264-A1 | PHARMACEUTICAL COMPOUNDS | USP19, USP18, UBE2I | SLC1A3 4309/4885SLC1A2 4518/4885SLC1A1 4147/4885 |
| US-11053213-B2 | Pharmaceutical compounds | USP19, USP18, UBE2I | SLC1A3 4309/4885SLC1A2 4518/4885SLC1A1 4147/4885 |
| US-11174291-B2 | Silstatin compounds | MSTN, CTSL, HGFAC | SLC1A3 4166/4885SLC1A2 4734/4885SLC1A1 4433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.